Elicio Therapeutics, Inc.

NASDAQ:ELTX

Biotechnology

Healthcare
$2.70 -18.90%

-$0.89 today

Market cap
$51.48M
Beta
1.14
P/E (TTM)
-1.7
EPS (TTM)
-$2.21
52W Low $2.66High $16.00

Volume 0.41M

Average 0.34M

ELTX Retained Earnings

Cumulative profits kept in the business rather than paid out as dividends.

Elicio Therapeutics, Inc.NASDAQ: ELTX

Retained Earnings · Q1 FY2026 · quarter ended Mar 2026

Retained earnings remains negative

Q1 FY2026 retained earnings was -$245.5M, compared with -$205.31M a year earlier.

Context

  • Retained earnings amounted to 1082.0% of total assets at the end of Q1 FY2026, up 352.5 pp from a year earlier.
  • Retained earnings grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether retained earnings keeps falling in the next quarterly balance sheet after a -19.6% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$245.5M-5.1% QoQ
Last fiscal yearDec 2025
-$233.67M-20.4% YoY
Year agoMar 2025
-$205.31M-19.6% since
Retained Earnings past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-19.6%——
1 year-20.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Retained Earnings history

USD · from the balance sheet

Latest · FY2025
(233.67M) USD
Year-over-year change
-20.4%

Retained Earnings vs competitors

How ELTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so retained earnings is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -19.6% is the 6th highest of 9, against a peer median of -17.5%.
  • Retained earnings amounts to 1082.0% of total assets for ELTX, versus a peer median of 319.7%.
ELTX Competitors
Retained Earnings for ELTX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
RANIRani Therapeutics Holdings, Inc.Mar 2026-$139.61M USD-26.7%—269.1%
ACTUActuate Therapeutics IncMar 2026-$160.23M USD-15.5%—1798.1%
ELTXElicio Therapeutics, Inc.Mar 2026-$245.5M USD-19.6%—1082.0%
MOLNMolecular Partners AGMar 2026-CHF 323.66M CHF-24.1%—370.3%
PEPGPepGen Inc.Mar 2026-$378.88M USD-25.6%—242.4%
CRDFCardiff Oncology, Inc.Mar 2026-$442.38M USD-11.3%—899.6%
MISTMilestone Pharmaceuticals Inc.Mar 2026-$456.67M USD-17.6%—235.7%
CRBPCorbus Pharmaceuticals Holdings, Inc.Mar 2026-$578.4M USD-17.1%—400.3%
NKTXNkarta, Inc.Mar 2026-$676.14M USD-17.3%—181.7%
Peer median (excluding ELTX) —-17.5%—319.7%

Competitors are the stored peer set for ELTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents88.76M7.8M12.89M17.62M18.56M
Short-term Investments00000
Net Receivables806K0000
Inventory00000
Other Current Assets379K36K895K1.28M73K
Total Current Assets91.25M10.72M16.35M20.69M19.31M
Property, Plant & Equipment (Net)4.44M8.5M7.28M6.19M5.08M
Goodwill00000
Intangible Assets00000
Long-term Investments723K617K0696K0
Tax Assets00000
Other Non-current Assets106K2.83M3.52M600K1.47M
Total Non-current Assets5.27M11.95M10.8M7.49M6.55M
Total Assets96.51M22.66M27.15M28.18M25.86M
Account Payables4.71M2.81M4.37M1.04M672K
Short-term Debt952K692K0901K0
Tax Payables00000
Deferred Revenue2.3M1.44M01.17M0
Other Current Liabilities2.06M444K2.57M2.31M2.53M
Total Current Liabilities11.3M6.87M9.76M11.52M8.11M
Long-term Debt00020.03M9.41M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities092K11K2.83M2.62M
Total Non-current Liabilities3.71M6.88M6.02M27.97M16.12M
Total Liabilities15.01M13.75M15.77M39.49M24.23M
Common Stock300K3K96K110K178K
Retained Earnings(215.14M)(107.01M)(142.2M)(194.1M)(233.67M)
Accumulated OCI(103K)0(197K)(175K)(127K)
Other Stockholders Equity226.01M0000
Minority Interest00000
Total Equity81.51M8.92M11.37M(11.31M)1.64M
Total Debt4.66M7.48M6.92M26.04M14.51M
Net Debt(84.09M)(316K)(5.98M)8.42M(4.05M)

Elicio Therapeutics, Inc.

NASDAQ:ELTX

Intrinsic Alpha fair value

Locked

Current Price

$2.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.